CorMedix Inc. (CRMD)
NASDAQ: CRMD · Real-Time Price · USD
6.07
-0.09 (-1.46%)
At close: Apr 1, 2025, 4:00 PM
6.02
-0.05 (-0.82%)
After-hours: Apr 1, 2025, 5:16 PM EDT
CorMedix Revenue
In the year 2024, CorMedix had annual revenue of $43.47M. CorMedix had revenue of $31.21M in the quarter ending December 31, 2024.
Revenue (ttm)
$43.47M
Revenue Growth
n/a
P/S Ratio
8.34
Revenue / Employee
$523,761
Employees
83
Market Cap
395.65M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 43.47M | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | 65.41K | -125.53K | -65.74% |
Dec 31, 2021 | 190.94K | -48.30K | -20.19% |
Dec 31, 2020 | 239.23K | -44.04K | -15.55% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
CRMD News
- 4 days ago - CorMedix: A Fair-Priced Biotech Company With A Bright Future - Seeking Alpha
- 7 days ago - CorMedix Inc. (CRMD) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 7 days ago - CorMedix Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 8 days ago - CorMedix Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Benzinga
- 14 days ago - CorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 25, 2025 - GlobeNewsWire
- 3 months ago - CorMedix Inc. Announces Preliminary Fourth Quarter 2024 Results and Provides Business Update - GlobeNewsWire
- 3 months ago - CorMedix Inc. Added to Nasdaq Biotechnology Index - GlobeNewsWire
- 4 months ago - CorMedix Inc. Supports CMS Policy Updates Regarding Access to Innovative Drug Products - GlobeNewsWire